Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Neuroblastoma: The Way Ahead

22.06.2007
Future directions for treatment of the childhood cancer Neuroblastoma, and a detailed analysis of current regimens, are included in a Seminar in this week’s edition of The Lancet.

Plans for the development of an International Neuroblastoma Risk Group (INRG) classification system, to develop a consensus to permit comparisons of outcomes of neuroblastoma patients worldwide, are also included in the Seminar, authored by Dr John Maris, Children’s Hospital of Philadelphia, USA, and colleagues. The INRG is currently analysing data obtained from 11,054 patients treated in Europe, Japan, USA, Canada, and Australia between 1974 and 2002 so that this international classification system can be created.

Neuroblastoma is a cancer of the sympathetic nervous system - the nerve network that regulates the “fight or flight” response to the environment. When solid tumours form, which can take the form of a lump or mass, they commonly begin in one of the adrenal glands, though they can also develop in nerve tissues in the neck, chest, abdomen, or pelvis.

It is the most common solid extracranial cancer in childhood, and represents more than 7% of all childhood malignant cancers and 15% of all childhood cancer deaths. It is remarkable for its broad spectrum of clinical behaviour. Likelihood of cure varies widely according to age at diagnosis, extent of disease, and tumour biology.

The authors say: “Although substantial improvement in outcome of certain well-defined subsets of patients has been observed during the past few decades, the outcome for children with a high-risk clinical phenotype has improved only modestly, with long-term survival still less than 40%.”

There are three main sets of presenting signs and symptoms, categorised as localised tumours, metastatic disease, and 4S disease. Around 40% of patients present with localised tumours which can vary in size and occur anywhere in the sympathetic nervous system. In certain locations these tumours can cause compression of the spinal cord and resulting motor weakness in 5-15% of patients. Around half of patients present with metastatic disease, which often involves multiple tumour burdens which can make patients quite ill. This type of tumour can also metastatise bony orbits, and can lead to symptoms such as raccoon eyes (periorbital bruises). 4S disease occurs in only 5% of patients with neuroblastoma – and presents as small localised primary tumours with secondary tumours in liver, skin or bone marrow that almost always spontaneously regress.

The treatment methods used in neuroblastoma management include surgery, chemotherapy, radiotherapy, and biotherapy, as well as observation alone in carefully selected circumstances.

But new approaches to relapsed disease for patients with high-risk neuroblastoma have developed in recent years. These include cytotoxic agents, targeted delivery of radionuclides, immunotherapy, retinoids, angiogenesis inhibitors, and tyrosine kinase inhibitors.

The authors conclude that improvements in understanding of the genomic alterations associated with tumour and behaviour and patient outcome have moved the goal of precise prognosis closer.

They say: “Improved understanding of normal neurodevelopment of the sympathicoadrenal stem will help us identify the key mutational events that initiate neuroblastoma tumorigenesis. Defining these events, as well as those that reliably predict for the acquisition of a high-risk phenotype, might ultimately direct us to the key pathways that can be exploited therapeutically.”

Tony Kirby | alfa
Further information:
http://www.thelancet.com/webfiles/images/clusters/thelancet/press_office/Seminar.pdf

More articles from Health and Medicine:

nachricht NTU scientists build new ultrasound device using 3-D printing technology
07.12.2016 | Nanyang Technological University

nachricht How to turn white fat brown
07.12.2016 | University of Pennsylvania School of Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

NTU scientists build new ultrasound device using 3-D printing technology

07.12.2016 | Health and Medicine

The balancing act: An enzyme that links endocytosis to membrane recycling

07.12.2016 | Life Sciences

How to turn white fat brown

07.12.2016 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>